By Ian Werther in News — 14 Mar 2026

South Korea's JW Holdings to acquire Soliders Investment, expanding biotech ties with U.S.

JW Holdings, the parent company of Korean drugmaker JW Pharmaceutical, has agreed to acquire a biotech-focused venture capital firm, Soliders Investment. The board approved the purchase of 2 million shares for 30.6 billion won, equivalent to about 2.45% of JW Holdings’ total assets. The deal brings the number of JW Holdings’ subsidiaries to seven.

Soliders Investment has backed several prominent Korean biotech firms, including Alteogen, Orum Therapeutics, and Olix. It manages healthcare-oriented investment funds such as the Global Healthcare Fund, Next Bio Star Investment, and Smart Bio Investment, focusing on early-stage biotech companies.

There is a rise of investment in clean technology supply changes projected for 2030 demonstrated in these graphs, shown through the annual manufacturing capacity for these technologies and the cumulative investment needs from the Net Zero by 2050 scenario. This graph was published as part of the International Energy Agency's Energy Technology Perspectives 2023 report. — Representative image for context; not directly related to the specific event in this article. License: CC BY 4.0. Source: Wikimedia Commons.

JW Holdings said the acquisition will expand its financial investment portfolio while strengthening its open innovation strategy with promising biotech firms. The company aims to merge its end-to-end R&D capabilities—spanning basic research, clinical development, and regulatory approval—with external biotech technologies to speed up drug development and foster growth through technology transfer and potential mergers and acquisitions.

In a statement, JW Holdings noted that the biotech investment environment has tightened, but strategic investments in firms with promising technologies remain increasingly important. The firm said the deal will broaden its biotech ecosystem and deepen open innovation tied to JW’s R&D strengths.

For U.S. readers, the move signals South Korea’s push to fuse corporate R&D with venture capital to accelerate biotech progress. Korea’s open-innovation approach could create new avenues for cross-border partnerships, licensing agreements, and potential supply-chain collaborations with American biopharma companies seeking access to Korea’s research pipeline and early-stage technologies.

View of the Union Investment-Skyscraper at a sunny winter day. This image is a panorama which was stitched from 4 images. Projection is flat. — Representative image for context; not directly related to the specific event in this article. License: CC BY-SA 3.0. Source: Wikimedia Commons.

The development reflects a broader trend of large Korean conglomerates expanding external investments to source breakthrough technologies and diversify growth engines beyond traditional manufacturing. If successful, JW’s strategy could feed into international collaboration and technology transfer that affect global drug development and markets.

Overall, the acquisition underscores Korea’s evolving biotech-financing ecosystem and its potential to influence both regional and global biotech collaboration, including opportunities for U.S. partners looking to access Korean research networks and early-stage innovations.

Subscribe to Journal of Korea